Alzheimer's disease is a complicated and debilitating disease that has no cure. One startup is testing whether a "disco" of light and sound can slow the disease in patients. Cognito Therapeutics ...
All products featured on WIRED are independently selected by our editors. However, we may receive compensation from retailers and/or from purchases of products through these links. Learn more. New ...
Top-tier investor syndicate led by FoundersX Ventures, with participation from all existing investors and new investors Alzheimer’s Drug Discovery Foundation (ADDF), Starbloom Capital, IAG Capital and ...
- Data will highlight durability of treatment effect and significant impact on slowing disease progression. - No treatment-related serious adverse events (SAEs) or incidents of amyloid-related imaging ...
Alzheimer’s disease serves as bookends to Brent Vaughan’s career so far. Twenty years ago, he worked for a Bay Area biotech whose pipeline included small molecules in development for the ...
Yesterday Cognito Therapeutics, a startup using visual and auditory stimulation to treat neurodegenerative disorders, announced Phase 2 trial results suggesting its gamma frequency neuromodulation ...
Cognito Therapeutics has raised $50 million in funding as it seeks to advance treatments for an elusive target: cognitive decline. Cognito, based in Cambridge, Mass., is developing a headset that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback